The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Impact of Oxypurinol in Patients With Symptomatic Heart Failure
Open accessAbstract
Objectives This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.Background Increased XO activity may contribute to heart failure pathophysiology.Methods Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life.Results The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by approximately 2 mg/dl (p < 0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA <9.5 mg/dl exhibited a trend towards worsening. In addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who worsened (-2.3 +/- 2.1 mg/dl vs. -1.0 +/- 1.9 mg/dl, p = 0.0006). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.Conclusions Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite these initial results, subsequent trials with larger number of patients have failed to report substantial positive effects as compared with the placebo groups (361, 405), although the meta-analysis of available studies indicates some improvement of cardiovascular function (430).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [405]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berry, C. E., & Hare, J. M. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055913 · Cited by 925
Self-citationAnker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065637.10517.a0 · Cited by 593
Casella, G., Carr, E., Davies, J. I., Belch, J. J. F., & Struthers, A. D. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 574
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D., Feng, L., Nakagawa, T., Kanellis, J., Lan, H. Y., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 562
Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure
Landmesser, U., Spiekermann, S., Dikalov, S., Tatge, H., Wilke, R., Kohler, C., Harrison, D. G., Hornig, B., & Drexler, H. (2002) · Circulation · doi:10.1161/01.cir.0000041431.57222.af · Cited by 525
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Self-citationPacker, M. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.25652 · Cited by 397
Spiekermann, S., Landmesser, U., Dikalov, S., Bredt, M., Gamez, G., Tatge, H., Reepschläger, N., Hornig, B., Drexler, H., & Harrison, D. G. (2003) · Circulation · doi:10.1161/01.cir.0000056762.69302.46 · Cited by 298
Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., & Drexler, H. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000258415.32883.bf · Cited by 210
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–393 of 393
Long, X., Wang, Z., & Yuan, W. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099442 · Cited by 4
Goutte et pathologies cardiovasculaires
Bardin, T., & Solal, A. C. (2011) · Revue du Rhumatisme · doi:10.1016/s1169-8330(11)70025-4 · Cited by 4
Cidade-Rodrigues, C., Cunha, F. M., Elias, C., Oliveira, D., Bettencourt, P., & Lourenço, P. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.032 · Cited by 4
Ghrelin mediated cardioprotection using in vitro models of oxidative stress
Kok, C., Ghossein, G., Igoor, S., Rao, R., Titus, T., Tsurusaki, S., Chong, J. J. H., & Kizana, E. (2024) · Gene Therapy · doi:10.1038/s41434-023-00435-9 · Cited by 4
Xanthine Oxidase Inhibitor Treatment of Hyperuricemia
Dalbeth, N., & Stamp, L. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2864-4.10013-2 · Cited by 4
Hey, C. Y., Barra, S., Duehmke, R. M., Pettit, S., Levy, W. C., Silva‐Cardoso, J., & Providencia, R. A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10216-y · Cited by 4
Temas de actualidad en insuficiencia cardiaca
Colet, J. C., Aguilera, R. M., Castillo, J. J. C., & Delgado, J. F. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)70044-2 · Cited by 4
Risk Factors for Mortality with Heart Failure
Aaronson, K. D., & MANCINI, D. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6001-7.00005-1 · Cited by 4
Uric Acid, Xanthine Oxidase and Heart Failure: Unresolved Issues
Verdejo, H., Greig, D. P., Castro, P., Alcaíno, H., Garcı́a, L., Chiong, M., Lavandero, S., Pizarro, M., & Alcaíno, H. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.10.006 · Cited by 4
Hyperuricaemia elevates risk of short-term readmission and mortality in patients with heart failure
Rao, J., Lai, R., Jiang, L., Wen, W. X., & Chen, H. (2024) · Open Heart · doi:10.1136/openhrt-2024-002830 · Cited by 3
Sabaka, P., Dukát, A., Gajdošík, J., Čaprnda, M., Bendžala, M., & Šimko, F. (2019) · Physiological Research · doi:10.33549/physiolres.934186 · Cited by 3
Heart Failure in Rheumatic Disease
Løgstrup, B. B. (2022) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2022.08.003 · Cited by 3
NLRP3 Inflammasome — a new universal target of asymptomatic hyperuricemia and gout management
Lebedev, P. A., Volova, L. T., Ossina, N., & Владимировна, П. Е. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3018 · Cited by 3
Overview of Oxidative Stress and Cardiovascular Disease
Elahi, M. M., Chuang, A., & Matata, B. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_42 · Cited by 3
High-Dose Prednisone in Patients With Heart Failure and Hyperuricemia: Friend and Foe?
de Denus, S., & Rouleau, J. L. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.01.007 · Cited by 3
Kamel, A. M., Ismail, B., Hafiz, G. A., Sabry, N. A., & Farid, S. F. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0019 · Cited by 3
Butts, B., Herring, C. H., Madariaga, A., Graven, L. J., Higgins, M. K., & Dunbar, S. B. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.07.001 · Cited by 2
AbuBaha, M., Zahran, A., Nouri, A., Bdair, M., Hamshary, H., Fuqha, H., Abubaha, B., Noori, F., Khaled, A., Awashra, A., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70197 · Cited by 2
Kuwabara, M., Cicero, A. F. G., Akashi, N., Oginö, K., Ae, R., Kohro, T., Kosami, K., Kojima, S., Kanbay, M., Andrés-Hernando, A., et al. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.07.009 · Cited by 2
Obstructive Sleep Apnea: A Contributing Factor in Gout
Khandwala, P., Desai, D., & Sen, M. (2024) · Cureus · doi:10.7759/cureus.52115 · Cited by 2
Biomarkers of Risk Stratification in Congestive Heart Failure: North American View
Tang, W. H. W. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.52 · Cited by 2
Rosenbaum, A. N., Duval, S., Adatya, S., Khan, M. B., John, R., & Eckman, P. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.197 · Cited by 2
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2012) · The Open Clinical Chemistry Journal · doi:10.2174/1874241601003010044 · Cited by 2
Common health problems management uncertainties in heart failure: a qualitative study.
Gastelurrutia, P., Gastelurrutia, M. Á., Faus, M. J., & Bayés‐Genís, A. (2012) · PubMed · doi:10.7399/fh.2012.36.6.51 · Cited by 2
Pharmacologic Management of Heart Failure in the Ambulatory Setting
Givertz, M. M., & Cohn, J. N. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50020-6 · Cited by 2
Self-citationLow acid uric in primary prophylaxis: worthy?
Aloia, E., & Sciaccaluga, C. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.065 · Cited by 2
Prognostic Role of Hyperuricemia in Acute Heart Failure
Franco, J., Formiga, F., Chivite, D., Cerdà, P., & Corbella, X. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.03.014 · Cited by 2
Can Xanthine Oxidase Inhibitors Improve Cardiac Function in Patients With Chronic Heart Failure?
Sugihara, S., Yamamoto, K., & Hisatome, I. (2016) · International Heart Journal · doi:10.1536/ihj.16-480 · Cited by 2
Shevchuk, O. O., Вольська, А. С., Yaremchuk, О. Z., Kurylo, K. I., Bardakhivska, K., Nikolaev, V. G., & Посохова, К. А. (2019) · Medical and Clinical Chemistry · doi:10.11603/mcch.2410-681x.2019.v.i3.10555 · Cited by 2
Pharmacologic Management of Heart Failure in the Ambulatory Setting
Givertz, M. M., & Cohn, J. N. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00012-6 · Cited by 2
Self-citationWakita, M., Asai, K., Kubota, Y., Koen, M., & Shimizu, W. (2021) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2021_88-518 · Cited by 2
Belevych, A. E., Terentyev, D. A., & Györke, S. (2009) · doi:10.1002/9780470561416.ch10 · Cited by 2
Doehner, W., Anker, S. D., & Filippatos, G. S. (2008) · Archives of Medical Science · Cited by 2
Clinical implications of longitudinally assessed uric acid in heart failure
Huang, L., He, C., Li, X., Xin, A., Zhou, P., Han, H., Feng, J., Zhai, M., Zhai, M., Zhang, Y., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103829 · Cited by 1
Zhou, Z., Ye, G., Ren, X., Cheng, Y., Cang, Y., Zhao, J., & Zhao, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1762413 · Cited by 1
Targeting Oxidative Stress in Heart Failure
Li, J. W. Y., & Tang, W. H. W. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_184 · Cited by 1
Something Old Holds Potential to Be Something New in Heart Failure: Allopurinol Revisited
Jaswal, J. S., Ussher, J. R., Lopaschuk, G. D., & Johnstone, D. E. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.001 · Cited by 1
Hiperuricemia y progresión del compromiso cardiorrenal crónico
Virú-Loza, M. A., & Palacios-Guillén, A. M. (2014) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2014.313.92 · Cited by 1
Hiperuricemia como fator de risco cardiovascular
Gabriel, E., de Almeida, A. P. F., & Saraiva, J. F. K. (2001) · Revista de Ciências Médicas · Cited by 1
Uric Acid as a Predictor of All-Cause Mortality in Heart Failure:
Meta-Analysis, A. (2011) · Cited by 1
Papel pronóstico de la hiperuricemia en insuficiencia cardiaca aguda
Franco, J., Formiga, F., Chivite, D., Cerdà, P., & Corbella, X. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.03.009 · Cited by 1
Do We Have a Chance to Translate Bench-top Results to the Clinic Adequately? An Opinion
Danielyan, K. E. (2017) · Translational medicine research · doi:10.1007/978-981-10-5804-2_26 · Cited by 1
Oxidative and Nitrosative Stress in Heart Failure
Sawyer, D. B., Liang, C., & Colucci, W. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5895-3.10012-9 · Cited by 1
Self-citationBiomarkers and Precision Medicine in Heart Failure
Ibrahim, N. E., Gaggin, H. K., & Januzzi, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00033-8 · Cited by 1
HEART FAILURE AND URATE-LOWERING THERAPY: CLINICAL ASPECTS
Барсуков, А. В., Борисова, Е. В., Дыдышко, В. Т., & Наумкина, П. И. (2022) · University therapeutic journal · doi:10.56871/3999.2022.69.27.002 · Cited by 1
Lillo‐Moya, J., Rojas-Solé, C., & Rodrigo, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19247-0.00009-6 · Cited by 1
Fernández, D., & Markenson, J. A. (2015) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-015-0016-5 · Cited by 1
Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?
Presta, V., Citoni, B., & Tocci, G. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02105-4 · Cited by 1
Oxidative Stress in Heart Failure
Sverdlov, A. L., Ngo, D. T. M., & Colucci, W. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00008-9 · Cited by 1
Self-citationBiomarkers in Acute Heart Failure: From Risk Markers to Therapeutic Targets
Kalogeropoulos, A. P., Georgiopoulou, V. V., & Butler, J. (2012) · Congestive Heart Failure · doi:10.1111/chf.12019 · Cited by 1
Costanzo, M. R. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1087 · Cited by 1
Liu-Shiu-Cheong, P. S. (2019) · Cited by 1
Adverse cardiovascular effects of allopurinol are related to the use of high doses
Bredemeier, M. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002218 · Cited by 1
Carter, S. J., HENDREN, N. S., & Grodin, J. L. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2516 · Cited by 1
Wakita, M. (n.d.) · Institutional Repositories DataBase (IRDB) · Cited by 1
Z kongresů, konferencí, symposií
(2009) · Cor et Vasa · doi:10.33678/cor.2009.132 · Cited by 1
Papel del estrés oxidativo y nitrosativo en la hipertrofia cardiaca y remodelación ventricular
Giraldo, A. (2019) · Acta Médica Colombiana · doi:10.36104/amc.2010.1570
Oxidative Stress and Redox Signalling in Cardiac Remodelling
Zhang, M., Sirker, A., & Shah, A. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-600-9_21
Seguimiento farmacoterapéutico y de la composición corporal en pacientes con insuficiencia cardiaca
Gastelurrutia, P. (2012) · Institutional Repository of the University of Granada (University of Granada)
Doehner, W., Anker, S. D., & Oginö, K. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.953901
The Role of Cytokines in Clinical Heart Failure
Mann, D. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800039-7.00014-1
Self-citationReaktívoxigén-származékok szerepe a szívműködés szabályozásában
Horváth, I., Kittka, B., Perjés, Á., Ruskoaho, H. J., & Szokodi, I. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30303
Uric Acid, Allopurinol: The Cardio-Renal Silver Bullet?
Covic, A. C., & Voroneanu, L. E. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_7
Jacqueline, M., Elías, R., Ángel, M., Segura, M., & Armando Rojas, R. (2009) · DOAJ (DOAJ: Directory of Open Access Journals)
Uric acid in chronic heart failure: marker or therapeutic
Patel, P. D., Arora, R. R., Doehner, W., Anker, S. D., & Filippatos, G. S. (2008)
Editorial High-Dose Prednisone in Patients With Heart Failure and Hyperuricemia: Friend and Foe?
de Denus, S., & Rouleau, J. L. (2013)
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez‐Castelao, A., Górriz, J. L., Bover, J., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.06.004
Ababei, M. S., Câmpeanu, A., Nistorescu, D., Zaharia, O., Gheorghe, G. S., Peride, I., Niculae, A., & Nanea, I. T. (2017) · Medicina Moderna - Modern Medicine
The effect of allopurinol on left ventricular mass in patients with treated essential hypertension
Gingles, C. (2019) · Discovery Research Portal (University of Dundee)
Associations between Allopurinol and Cardiovascular and Renal Outcomes in Diabetes
Weisman, A. (2020) · TSpace (University of Toronto)
Dulce, R. A., & González, D. R. (2018) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata)
National consensus on diagnosis and treatment of gout
Gancheva, R., Pavlova, P., & Kolarov, Z. (2020) · Rheumatology (Bulgaria) · doi:10.35465/29.s.2021.pp64-93
Temas de actualidad en insuficiencia cardiaca
Colet, J. C., Aguilera, R. M., Castillo, J. J. C., & Delgado, J. F. (2009) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(09)71775-3
Barylski, M., Batko, B. P., Filipiak, K. J., Mamcarz, A., Rell‐Bakalarska, M., Samborski, W., & Wiland, P. (2022) · Rheumatology Forum · doi:10.5603/rf.2022.0007
Biomarkers of Metabolic Syndrome in Cardiomyopathy: A Leading Cause of Heart Failure
Sharif, S., Rafaqat, S., & Naz, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109381
Lin, Y., Pang, L., Huang, S., Shen, J., Wu, W., Tang, F., Su, W., Zhu, X., Sun, J., Quan, R., et al. (2023) · Cardiology · doi:10.1159/000530206
Güvenç, R. Ç., & Naser, A. (2023) · Turkiye Klinikleri Cardiovascular Sciences · doi:10.5336/cardiosci.2023-96729
Wang, Y., Chen, K., Zhou, S., Qiao, Z.-X., & Bao, X. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/9946667
Gupta, P. K., Boro, A. K., Paul, B., Rahman, H., Barman, A., Sarkar, P., & Gang, S. (2023) · Heart India · doi:10.4103/heartindia.heartindia_25_23
The Role of Uric Acid in Hypertension and Heart Failure
Borghi, C., Adorno, A., Gallelli, I., & Dall’Olio, M. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_10
Review on Allopurinol in the Treatment of Gout
Aryan, A., Sahani, V., & Patil, S. M. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.3.6.9
Ye, L., Xu, A., Huang, J., Zhang, Y., Yao, J., & Wang, F. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03848-0
Cardio-rheumatology: present and future. Part II
Ma, Y., Wang, Z., Vi, M., Trofimov, E. A., & Bashkinov, R. A. (2025) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov637317
Drug Repurposing for Cardioprotective Therapy
Negi, S., Jadhav, K., Singh, R., Jhilta, A., & Verma, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_4
Lebedev, P. A., Владимировна, П. Е., & Lebedeva, S. P. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-235-3-217-225
Mutation of a single cysteine in CaMKIIδ protects the heart from ischemia-reperfusion InjuryPreprint
Machado, N. R., Sun, J., Noguchi, A. C., Springer, D., Liu, C., Murphy, E., & Levine, R. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.721066
Ibănescu, R., Ciurescu, S., Buzaș, R., Militaru, A. G., Mîțu, D.-A., Ionică, L. N., Goje, I.-D., Rachieru, C., Ciubotaru, P. G., Ivan, V. S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145719
Protein S-nitrosylation in the heart: Mechanisms, physiological roles, and pathological remodeling
Gouin-Gravezat, M., Boulghobra, D., Grandperrin, A., Alpha‐Bazin, B., Cazorla, O., & Reboul, C. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104414
Metadata
- Authors
- Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P.
- Affiliations
- University of Miami (US)
- Cardiome (Canada) (CA)
- Rutgers, The State University of New Jersey (US)
- Boston University (US)
- Toronto General Hospital (CA)
- Brigham and Women's Hospital (US)
- Corresponding author
- Hare, Joshua M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 51
- Issue
- 24
- Pages
- 2301-2309
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1414418298
- Cited by
- 392
- References
- 25
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 18 · 2023: 21 · 2022: 21 · 2021: 18 · 2020: 34 · 2019: 33 · 2018: 20 · 2017: 8 · 2016: 23 · 2015: 16 · 2014: 26 · 2013: 18 · 2012: 41
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- oxypurinol, xanthine oxidase inhibition, heart failure, systolic dysfunction, serum uric acid, hyperuricemia, biomarkers, quality of life
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Enzyme Inhibitors, Female, Health Status Indicators, Heart Failure, Humans, Male, Middle Aged, Oxypurinol, Quality of Life, Surveys and Questionnaires, Systole, Uric Acid, Xanthine Oxidase, Natriuretic Peptide, Brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
